Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population

Scandinavian Journal of Gastroenterology
Marte Lie HøivikAsle W Medhus

Abstract

Long-term data regarding switching from originator infliximab to biosimilar CT-P13 are sparse. Concerns about increased immunogenicity after switching have been raised. We aimed to study the effectiveness, safety and immunogenicity after switching from originator infliximab to CT-P13 in a real-world IBD population with 18 months prospective follow-up. All adult IBD patients treated with originator infliximab at the Department of Gastroenterology, Oslo University Hospital, were switched to CT-P13 and followed prospectively for 18 months. The primary endpoints were (i) the proportion of patients remaining on CT-P13 18 months after switching and (ii) immunogenicity during 18 months after switching. The secondary endpoints included (i) adverse events, (ii) changes in disease activity, C-reactive protein, anaemia, faecal calprotectin, infliximab dose and interval and p-infliximab. In total, 143 IBD patients were switched, 99 with Crohn's disease and 44 with ulcerative colitis. Altogether, 130 (91%) remained on CT-P13 throughout 18 months. Two patients developed ADAs at moderate level and discontinued CT-P13. Another 10 patients discontinued CT-P13 (two due to loss of response without ADAs, four due to adverse events, and four in rem...Continue Reading

References

Jun 6, 2002·Lancet·Stephen B HanauerUNKNOWN ACCENT I Study Group
Dec 13, 2005·The New England Journal of Medicine·Paul RutgeertsJean Frédéric Colombel
Jul 16, 2008·Inflammatory Bowel Diseases·James D LewisJonas H Ellenberg
Jan 26, 2010·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Severine VermeirePaul Rutgeerts
Nov 1, 2013·Alimentary Pharmacology & Therapeutics·M L HøivikUNKNOWN IBSEN study group
Jun 21, 2015·Journal of Crohn's & Colitis·Lev LichtensteinBatia Weiss
Aug 19, 2015·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Sarah S ThomasDaniel E Furst
Sep 24, 2015·Expert Review of Gastroenterology & Hepatology·Shomron Ben-HorinYehuda Chowers
Apr 23, 2016·PloS One·Mirthe E van der ValkUNKNOWN COIN study group and the Dutch Initiative on Crohn and Colitis
Dec 9, 2016·Journal of Crohn's & Colitis·Silvio DaneseLaurent Peyrin-Biroulet
May 18, 2017·Journal of Crohn's & Colitis·Marcus HarbordUNKNOWN European Crohn’s and Colitis Organisation [ECCO]
Jul 2, 2017·Digestive Diseases and Sciences·Lisa J T SmitsFrank Hoentjen
Sep 14, 2017·European Journal of Gastroenterology & Hepatology·Federico Argüelles-AriasManuel Romero Gómez
Jan 26, 2018·European Journal of Clinical Pharmacology·N W BooneA A van Bodegraven
Feb 8, 2018·Applied Health Economics and Health Policy·Don HusereauCarl Selya-Hammer

❮ Previous
Next ❯

Citations

Oct 21, 2018·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Cristina ScavoneAnnalisa Capuano
May 7, 2019·Expert Opinion on Biological Therapy·Christopher J EdwardsAurelian Amiot
Jul 16, 2019·Expert Review of Clinical Pharmacology·Anne S StrikMark Löwenberg
Jul 20, 2019·Expert Review of Gastroenterology & Hepatology·Laurent Peyrin-BirouletTaegyun Kang
Aug 14, 2019·Expert Opinion on Biological Therapy·Ahmad Albshesh, Shomron Ben-Horin
Aug 18, 2020·Expert Opinion on Biological Therapy·Tommaso Lorenzo ParigiSilvio Danese
Apr 26, 2019·Therapeutic Advances in Gastroenterology·Ágnes MilassinTamás Molnár
Jul 2, 2019·Therapeutic Advances in Gastroenterology·María Fernanda Guerra VelozFederico Argüelles-Arias
Dec 12, 2018·Digestive Diseases and Sciences·Nikolas PlevrisCharlie W Lees
Nov 14, 2019·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Vibeke StrandJohn D Isaacs
May 2, 2020·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Sang Joon LeeSeul Gi Lee
Sep 14, 2020·Journal of Digestive Diseases·Saurabh Talathi, Kondal R Kyanam Kabir Baig
Oct 30, 2020·European Journal of Hospital Pharmacy. Science and Practice·Nerea Martín-GutiérrezMaría José Otero
Jul 10, 2021·Journal of Comparative Effectiveness Research·Brian GodmanJohanna C Meyer
Aug 25, 2020·Bulletin de l'Académie nationale de médecine·P Lechat

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrophic Gastritis

Atrophic Gastritis is a process where gastric glandular cells are lost and replaced with firbous tissues, as a result of chronic inflammation. Learn more about Atrophic Gastritis here.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.